All News
Filter News
Found 808,644 articles
-
Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
12/2/2020
APVO442 is a Unique T-Cell Engager Designed to Target PSMA and CD3 for the Treatment of Prostate Cancer
-
StageZero Life Sciences Announces Initiation of Testing for Travel to China
12/2/2020
StageZero Life Sciences, Ltd. (TSX:SZLS) ("StageZero" or the "Company") announced today that it has initiated COVID-19 testing for travel to China with its partners in Canada.
-
Study: COVID-19 Mortality Rate Declined 75% Since First Hospitalized Cases, but Concerns Remain for N.J.'s Second Wave
12/2/2020
As New Jersey confronts an intense second wave of COVID-19, one key finding from the first months of the pandemic provides a note of hope: The mortality rate for patients hospitalized with the disease in New Jersey dropped from 25.3 percent during April to 6 percent in August.
-
Syneos Health Announces Pricing of Secondary Offering of Common Stock - Dec 02, 2020
12/2/2020
Syneos Health, Inc. announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 6,000,000 shares of the Company’s common stock at a price to the public of $61.90 per share.
-
Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million
12/2/2020
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares
-
Assure Holdings Announces Closing of US$10.5 Million Institutional Investor Private Placement
12/2/2020
Assure Holdings Corp. is pleased to announce that it has closed its previously announced brokered private placement of 16,357,703 units of the Company at an issue price of US$0.64 per Unit, for gross proceeds of US$10,468,930.
-
COVID-19 Vaccine Capable Air Transportation System Patent Awarded to Reflect Scientific for its Liquid Nitrogen Temperature-controlled Cooling and Freezing Systems
12/2/2020
Reflect Scientific, Inc., a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announced a patent has been granted by the United States Patent Office for an ultracold shipping and storage container for transportation by air that uses liquid nitrogen technology for cooling.
-
4D Molecular Therapeutics Strengthens Leadership Team with Key Appointments in Clinical Research and Development
12/2/2020
4D Molecular Therapeutics (4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therapies, announced that Robert Fishman, M.D. has joined as Chief Medical Officer & Therapeutic Area Head, Pulmonology; Raphael Schiffmann, M.D. has joined as Senior Vice President & Therapeutic Area Head, Cardiology; and Robert Kim, M.D., M.B.A. has joined as Senior Vice President & Clinical Therapeutic Area Head, Ophthalmology
-
CHOP Appoints Dr. Karen Zur as Chief of Division of Otolaryngology
12/2/2020
Zur has served as Interim Division Chief since March 2020 and also directs CHOP's Pediatric Voice Program
-
Reata Pharmaceuticals, Inc. Announces Pricing of Class A Common Stock Offering
12/2/2020
Reata Pharmaceuticals, Inc. (Nasdaq: RETA) (“Reata” or the “Company”), a clinical-stage biopharmaceutical company, today announced that it has priced a public offering of 2,000,000 shares by the Company of its Class A common stock at a price to the public of $140.85 per share, for gross proceeds of $281.7 million
-
Statement on UK's authorization of its first COVID-19 vaccine, manufactured by Pfizer/BioNTech
12/2/2020
Health Canada is aware that the UK Medicines and Healthcare Products Regulatory Agency has issued a temporary authorization for temporary limited supply of its first COVID-19 vaccine, manufactured by Pfizer/BioNTech.
-
DGAP-News: MorphoSys' Licensee Announces Approval by the European Commission for Tremfya(R) (guselkumab) for Treatment of Adults with Active Psoriatic Arthritis (PsA)
12/2/2020
MorphoSys AG announced that its licensee Janssen Research & Development, LLC. reported the European Commission's approval for the use of Tremfya in the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug therapy.
-
Camber Spine’s OLIF Retractor System Receives ‘2020 Best Spine Technology Award’
12/2/2020
Camber Spine , a leading innovator in spine and medical technologies has been presented with Orthopedics This Week’s “2020 Best Spine Technology Award” for its Lateral ALIF / OLIF Retractor System, an integral part of the OLIF (oblique lateral interbody fusion) technique for anterior column reconstruction
-
ABMC Uplists to the OTCQB Venture Market
12/2/2020
American Bio Medica Corporation announced their common shares were approved for listing on OTC Markets Group Inc.'s OTCQB® Venture Market.
-
Walgreens and VillageMD to Open the Next 40 Full-Service Primary Care Clinics
12/2/2020
Walgreens Boots Alliance and VillageMD announced plans to open the next 40 new Village Medical at Walgreens full-service primary care clinics by the end of summer 2021.
-
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with Inhibitors
12/2/2020
Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors that will enter a pivotal Phase 3 study CRIMSON 1 this m
-
Codexis Announces Proposed Public Offering of Common Stock
12/2/2020
Codexis, Inc. (Nasdaq:CDXS), a leading protein engineering company, today announced that it has commenced an underwritten public offering of shares of its common stock.
-
Lilly announces 650,000 additional doses of neutralizing antibody bamlanivimab (LY-CoV555) purchased by U.S. government to treat COVID-19
12/2/2020
The U.S. government has purchased 650,000 additional doses of Eli Lilly and Company's (NYSE: LLY) neutralizing antibody bamlanivimab (LY-CoV555) 700 mg.
-
Tetra Bio-Pharma Completes Major Milestone for COVID-19 Therapeutic
12/2/2020
Tetra Bio-Pharma Inc. ( TSX:TBP ) ( OTCQB:TBPMF ), a leader in cannabinoid-derived drug discovery and development, today announced it has completed Investigational New Drug (IND) -enabling toxicology, clearing the way for human clinical trials for its novel drug candidate ARDS-003.
-
Bora Pharmaceuticals Selects Mississauga for its North American Headquarters
12/2/2020
Bora Pharmaceuticals, a leading international contract development and manufacturing organization, has selected Mississauga as the location for its first manufacturing facility and corporate headquarters in North America.